Scantox Group has released the 2023 Annual Report today. It highlights the many activities our company has done over the year to shape the future of a business that in so many ways contribute to improve lives worldwide through the development of new drugs and treatments.
Martin Amtoft-Christensen, CFO Scantox Group : ”We are pleased to deliver a satisfactory operational result in a year with strong organic revenue growth while successfully incorporating two new businesses and look forward to integrating QPS Neuropharmacology in 2024”.
